Neurocrine Biosciences Reports New INGREZZA Data in Tardive Dyskinesia
SAN DIEGO, June 8, 2026 Neurocrine Biosciences announced new clinical findings demonstrating the long-term effectiveness of INGREZZA® (valbenazine) capsules...
VMAT2 inhibitor
Advertisement
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Teva Presents New AUSTEDO Data Supporting Sustained TD Treatment
PARSIPPANY, New Jersey, USA & TEL AVIV, Israel – June 8, 2026 Teva Pharmaceuticals has unveiled new real-world and...
Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
Teva Reports New AUSTEDO Data in Huntington’s Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
Advertisements
Neurocrine Shows INGREZZA Persistence Edge in TD Study
SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...
Advertisement
